Suzhou Highfine Biotech Co Ltd

Suzhou Highfine Biotech maintains a strong liquidity position, with a current ratio of 26.78, indicating that its current assets significantly exceed its current liabilities. The company is nearly debt-free, with a debt-to-equity ratio of 0.0, and long-term debt of only CNY 3.9 million. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential liquidity constraints if short-term obligations increase.

Profitability metrics show a return on equity (ROE) of 1.62% and a return on assets (ROA) of 1.56%, both below the typical thresholds for high-margin chemical firms. The company’s net income of CNY 35.98 million in the latest period reflects a healthy margin, but the ROE and ROA suggest that asset efficiency and equity returns are modest relative to industry expectations.

The company operates as a single business segment, with no disclosed geographic diversification in revenue. All operations are based in China, and the company does not report revenue by region, indicating a high concentration of exposure to the domestic market.

Looking ahead, the company’s revenue is expected to grow, though the exact rate is not specified. Historical revenue of CNY 133.83 million provides a baseline for future performance. The company’s capital expenditures of CNY -25.4 million suggest a net cash inflow from operations, but the negative value may indicate a reduction in CAPEX or a reversal of prior investments.

The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. While dilution risk is currently low, the company’s capital structure and financing activities should be monitored for any changes in equity dilution potential. No recent filings or transcripts have been provided to indicate material events affecting the company’s operations or strategy.

The company has not disclosed any material recent events, such as earnings calls, regulatory actions, or strategic announcements, that would impact its near-term outlook. The absence of such disclosures suggests a stable but uneventful operating environment.

Zero debt-to-equity ratio provides a strong balance sheet position, ranking above the 75th percentile of peers.

Revenue grew 33.3% year-over-year to 602 million CNY, demonstrating strong top-line expansion momentum.

Cash conversion ratio of 1.66 exceeds the cohort median of 1.1, suggesting efficient cash generation.

Return on equity of 1.6% falls below the 3.6% cohort median, indicating inefficient capital utilization.

Revenue ¥388.8M, −13,1% YoY; Operating income −24,5% YoY.

• ▍Revenue ¥388.8M, −13,1% YoY
• ▍Operating income −24,5% YoY
• ▍Net income −23,5% YoY
• ▍Free cash flow −157,3% YoY
• ▍Net margin 25.5%